Abstract: A display module includes a display panel having a fingerprint identification area and a light-transmitting protective film located on a back surface of the display panel. The light-transmitting protective film includes a protective layer, a light-shielding pattern located on a side of the protective layer, and a light-transmitting adhesive layer located on a side of the light-shielding pattern away from the protective layer. The protective layer has a target area. At least the target area is a light-transmitting area, and the target area at least partially overlaps with the fingerprint identification area. The light-shielding pattern defines a plurality of imaging apertures, the plurality of imaging apertures are arranged at intervals, and orthogonal projection of the plurality of imaging apertures on the protective layer are at least located in the target area. A surface of the light-transmitting adhesive layer away from the light-shielding pattern is in contact with the display panel.

Abstract: A related substance of linagliptin intermediate 2-(chloromethyl)-4-methylquinazoline, 4,4?-(2-methylpropane-1,3-diyl)bis(2-(chloromethyl)quinazoline) and a method for synthesizing the related substance (impurity) by reacting 2-(chloromethyl)-4-methylquinazoline with acetaldehyde under an alkaline condition and a purification method are provided. The preparation method is simple and convenient to operate, short in reaction time, high in product purity, and high in yield. The synthesized related substance can be used for qualitative and quantitative analysis of the linagliptin intermediate 2-(chloromethyl)-4-methylquinazoline and API impurities of linagliptin, so that the medication safety of the linagliptin is improved.

Abstract: A method and system for positioning a target in a brain region are provided. The method includes: obtaining datasets of N persons at a first time point and a second time point after stroke; constructing a first lesion mapping functional network based on each resting-state functional magnetic resonance imaging image in a first stroke dataset; constructing an acute phase cognitive-lesion mapping functional network; constructing a chronic phase cognitive-lesion mapping functional network; comparing the acute phase cognitive-lesion mapping functional network with the chronic phase cognitive-lesion mapping functional network to obtain a key improvement network; calculating a whole-brain functional connectivity network with each voxel as a seed point, and performing spatial correlation calculation on the whole-brain functional connectivity network and the key improvement network to obtain a spatial correlation network; and determining a therapeutic target of the functional image to be positioned.

Abstract: The present disclosure relates to a broadcast directing method, apparatus and system, and a non-transitory computer-storable medium, which relate to the technical field of computers. The broadcast directing method includes acquiring a reference video stream from a reference camera position; performing event recognition on the reference video stream to obtain at least one reference event frame interval; determining a local sequence of each reference event frame interval according to a correspondence relationship between the event and a camera position identification, the local sequence comprising a camera position identification of each frame image of a video to be played corresponding to the reference event frame interval and a frame identification corresponding to the camera position identification; generating a broadcast directing sequence according to the local sequence; and generating a broadcast directing video according to the broadcast directing sequence and a video stream of a camera position.

Abstract: The present invention resides in the discovery that altered abundance of fungal species in the gut and feces of both fecal microbiota transplantation (FMT) donors and recipients may influence the outcome of FMT treatment. Thus, novel methods are provided for identifying subjects as suitable donor or recipients for FMT, for assessing the likelihood of FMT treatment success, and for enhancing FMT treatment efficacy. Also provided are kits and compositions for FMT with enhanced efficacy.

Abstract: Methods are provided for treating metabolic diseases by way of modulating recipients' gastrointestinal tract microorganism profile such as by fecal microbiota transplantation (FMT) treatment. Also provided are methods for assessing a patient's risk of developing obesity and/or related metabolic diseases. Further provided are kits and compositions for use in these methods.

Abstract: Methods are provided for treating COVID-19 patients to facilitate their recovery from the disease as well as for prognosis of severity of COVID-19 among patients who have been infected by SARS-CoV-2. Also provided are kits and compositions for use in these methods.

Abstract: Certain microorganism species in a composition for use in fecal microbiota transplantation (FMT), including fecal material obtained from an FMT donor, can affect the outcome of FMT treatment such as regulating the bodyweight and cholesterol level in FMT recipients. Thus, methods are provided for identifying subjects as suitable donor to optimize FMT outcome and for pretreating donors and/or recipients for optimized FMT outcome. Also provided are kits and compositions for improving FMT outcome, including for bodyweight and/or cholesterol reduction.

Abstract: The present invention resides in the discovery that abundance and diversity of viral species in the fecal matter from a donor used in fecal microbiota transplantation (FMT) treatment can influence the outcome of the FMT treatment. Thus, novel methods are provided for identifying subjects as suitable donors for FMT, for assessing the likelihood of FMT treatment success, and for enhancing FMT treatment efficacy. Also provided are kits and compositions for FMT with enhanced efficacy.

Abstract: Methods are provided for identifying subjects as suitable donor or recipients for FMT, for assessing the likelihood of FMT treatment success, and for enhancing FMT treatment efficacy. Also provided are kits and compositions for FMT with enhanced efficacy.

Abstract: The present invention resides in the discovery that abundance and diversity of viral species in the fecal matter from a donor used in fecal microbiota transplantation (FMT) treatment can influence the outcome of the FMT treatment. Thus, novel methods are provided for identifying subjects as suitable donors for FMT, for assessing the likelihood of FMT treatment success, and for enhancing FMT treatment efficacy. Also provided are kits and compositions for FMT with enhanced efficacy.

Abstract: Provided herein are methods of treating a cancer in a subject comprising administering a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Methods of altering a phenotype of a cancer cell or tumor cell, methods of inhibiting growth of such cells, and methods of inducing apoptosis of these cells are also provided herein. These methods comprise contacting the cell with a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Further provided herein are diagnostic methods, comprising comparing the expression or structure of a FOXP3 protein or FOXP3 gene in a test sample to that of a normal or prior sample. A method of screening a test compound for anti-cancer activity comprising administering to cells the test compound and measuring FOXP3 protein or FOXP3 gene expression is moreover provided herein.

Abstract: Provided herein are methods of treating a cancer in a subject comprising administering a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Methods of altering a phenotype of a cancer cell or tumor cell, methods of inhibiting growth of such cells, and methods of inducing apoptosis of these cells are also provided herein. These methods comprise contacting the cell with a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Further provided herein are diagnostic methods, comprising comparing the expression or structure of a FOXP3 protein or FOXP3 gene in a test sample to that of a normal or prior sample. A method of screening a test compound for anti-cancer activity comprising administering to cells the test compound and measuring FOXP3 protein or FOXP3 gene expression is moreover provided herein.

Abstract: This invention concerns particulate reinforced Al-based composites, and the near net shape forming process of their components. The average size of the reinforced particle in the invented composites is 0.1–3.5 ?m and the volume percentage is 10–40%, and a good interfacial bonding between the reinforced particulate and the matrix is formed with the reinforced particles uniformly distributed. The production method of its billet is to have the reinforced particles and Al-base alloy powder receive variable-speed high-energy ball-milling in the balling drum. Then, with addition of a liquid surfactant, the ball-mill proceeds to carry on ball-milling. After the ball-milling, the produced composite powder undergoes cold isostatic pressing and the subsequent vacuum sintering or vacuum hot-pressing to be shaped into a hot compressed billet, which in turn undergoes semisolid thixotropic forming and may be shaped into complex-shaped components. These components can be used in various fields.

Abstract: This invention concerns particulate reinforced Al-based composites, and the near net shape forming process of their components. The average size of the reinforced particle in the invented composites is 0.1˜3.5 &mgr;m and the volume percentage is 10˜40%, and a good interfacial bonding between the reinforced particulate and the matrix is formed with the reinforced particles uniformly distributed. The production method of its billet is to have the reinforced particles and Al-base alloy powder receive variable-speed high-energy ball-milling in the balling drum. Then, with addition of a liquid surfactant, the ball-mill proceeds to carry on ball-milling. After the ball-milling, the produced composite powder undergoes cold isostatic pressing and the subsequent vacuum sintering or vacuum hot-pressing to be shaped into a hot compressed billet, which in turn undergoes semisolid thixotropic forming and may be shaped into complex-shaped components. These components can be used in various fields.